Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8387199 | 0.79 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL3817278 | 0.78 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL13049649 | 0.78 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL14586465 | 0.78 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL29271046 | 0.77 | GAA (0.62) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL18380993 | 0.77 | GAA (0.62) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL23196350 | 0.77 | GAA (0.62) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL561353 | 0.74 | GAA (0.59) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL14618075 | 0.74 | GAA (0.59) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL23196348 | 0.74 | GAA (0.58) | GAANPSR1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271296-A | Pseudo-uridine, preparation method and application thereof | 北京安必奇生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-114940676-B | Synthesis method of pseudouridine | 天津全和诚科技有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115894458-A | Novel modified nucleoside and application thereof in nucleic acid medicine | 合肥华纳生物医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114940676-A | Synthesis method of pseudouridine | 天津全和诚科技有限责任公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-3251674-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BioCryst Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| WO-1999026944-A1 | NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS | ASTRAZENEKA UK LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999005123-A1 | NOVEL PYRIMIDIN DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999002501-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998054180-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | disclosed |
| US-5576429-A | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRICIDE; ANTITUMOR AGENT | MEDIVIR AB (SE) | 1996-11-19 | — | — | US | disclosed |
| EP-0357571-B1 | Pyrimidine nucleosides | MEDIVIR AB (SE) | 1996-04-03 | — | — | EP | disclosed |
| EP-0691333-A2 | Pyrimidine derivatives, process for their preparation and their use as precursors | Medivir Aktiebolag (SE) | 1996-01-10 | — | — | EP | disclosed |
| US-5440040-A | Drug for Aids therapy; viricides | MEDIVIR AB (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0357571-A2 | Pyrimidine nucleosides | Medivir Aktiebolag (SE) | 1990-03-07 | — | — | EP | disclosed |
| WO-1989012061-A1 | PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES | MEDIVIR AB (SE) | 1989-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | GAA 246/4885NPSR1 4135/4885ATM 4521/4885 |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | GAA 60/4885NPSR1 3263/4885ATM 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.